Advertisement

Digestive Diseases and Sciences

, Volume 47, Issue 12, pp 2763–2768 | Cite as

An Open-Label Trial of Theophylline for Functional Chest Pain

  • Satish S.C. Rao
  • Ranjit S. Mudipalli
  • Victor Mujica
  • Craig L. Utech
  • Xing Zhao
  • Jeffrey L. Conklin
Article

Abstract

Visceral hypersensitivity may play a role in the pathogenesis of functional chest pain, although the underlying mechanism(s) is unknown. We investigated the effects of theophylline, an adenosine receptor antagonist, on sensory perception and biomechanical properties of esophagus in patients with functional chest pain. Esophageal balloon distention was performed using impedance planimetry in 21 consecutive patients with functional chest pain. Patients found to have a hypersensitive esophagus received intravenous theophylline and balloon distension was repeated. If the hypersensitivity improved, oral theophylline was prescribed for three months as an open label trial. Balloon distension reproduced typical chest pain in 16 (76%) patients at thresholds suggestive of hypersensitivity. After theophylline infusion, pain thresholds increased in 12 (75%) patients. Median threshold pressures for discomfort and pain improved (P < 0.01). Cross-sectional area increased (P < 0.05) and the tension/strain association shifted to the right (P < 0.01). Seven of eight patients reported sustained improvement in pain after oral theophylline. Theophylline may ameliorate chest pain in patients with hypersensitive esophagus, possibly by altering adenosine-mediated nociception.

functional chest pain esophageal hypersensitivity theophylline adenosine receptor antagonism 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Clouse RE, Richter JE, Heading RC, Jannssens J, Wilson JA: Functional esophageal disorders. In Rome II: The Functional Gastrointestinal Disorders. AD Drossman, E Corazziari, NJ Talley, WG Thompson, and WE Whitehead (eds). McLean, Virginia, Degnon Associates, 2000, pp 247–298Google Scholar
  2. 2.
    Ockene IS, Shay MJ, Alpert JS, Weiner BH, Dalen JE: Unexplained chest pain in patients with normal coronary arteriograms: a follow up study of functional status. N Engl J Med 303(22):1249–1252, 1980Google Scholar
  3. 3.
    Ward BW, Wu WC, Richter JE, Hackshaw BT, Castell DO: Long-term follow up of symptomatic status of patients with noncardiac chest pain; is diagnosis of esophageal etiology helpful? Am J Gastroenterol 82(3):215–218, 1987Google Scholar
  4. 4.
    Barish CF, Castell DO, Richter JE: Graded esophageal balloon distention: a new provocation for non-cardiac chest pain. Dig Dis Sci 31(12):1292–1298, 1986Google Scholar
  5. 5.
    Katz PO, Dalton CB, Richter JE, Wu WC, Castell DO: Esophageal testing in patients with non-cardiac chest pain or dysphagia-results of three years' experience with 1161 patients. Ann Int Med 106(4):593–597, 1987Google Scholar
  6. 6.
    Richter JE, Barish CF, Castell DO: Abnormal Sensory perception in patients with esophageal chest pain. Gastroenterology 91(4):845–852, 1986Google Scholar
  7. 7.
    Deschner WK, Maher KA, Calttau L Jr, Benjamin SB: Intraesophageal balloon distention vs drug provocation in the evaluation of non-cardiac chest pain. Am J Gastroenterol 85(8):938–943, 1990Google Scholar
  8. 8.
    Rao SSC, Gregersen H, Hayek B, Summers RW, Christensen J: Unexplained chest pain: The hypersensitive, hyperreactive and poorly compliant esophagus. Ann Intern Med 124(11):950–958, 1996Google Scholar
  9. 9.
    Cervero F, Janig W: Visceral nociceptors: a new world order? Trends Neurosci. 15(10):374–378, 1992Google Scholar
  10. 10.
    Mayer EA, Gebhart GF: Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 107(1):271–293, 1994Google Scholar
  11. 11.
    Sarkar S, Aziz Q, Woolf CJ, Hobson AR, Thompson DG: Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 356(9236):1154–1159, 2000Google Scholar
  12. 12.
    Varaia I, Logue E, O'Connor C, Newby K, Wagner HR, Davenport C, et al: Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 140(3):367–372, 2000Google Scholar
  13. 13.
    Sawynok J: Adenosine receptor activation and nociception. Eur J Pharmacol 347(1):1–11, 1998Google Scholar
  14. 14.
    Bueno L, Fioramanti J, Delvaux M, Frexinos J: Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 112(5):1714–1743, 1997Google Scholar
  15. 15.
    Sylven C, Beerman B, Jonzon B, Brandt R: Angina pectoris like pain provoked by intravenous adenosine in healthy volunteers. BMJ 293(6541):227–230, 1986Google Scholar
  16. 16.
    Crea F, Pupita G, Galassi AR, el-Tamimi H, Kaski JC, Davies G, et al: Role of adenosine in pathogenesis of anginal pain. Circulation 81(1):164–172, 1990Google Scholar
  17. 17.
    Gaspardone A, Crea F, Tomai F, Versaci F, Iamele M, Gioffre G, et al: Muscular and cardiac adenosine-induced pain is mediated by A1 receptors. J Am Coll Cardiol 25(1):251–257, 1995Google Scholar
  18. 18.
    Bleehen T, Keele CA: Observation on the algogenic actions of adenosine compounds on the human blister base preparation. Pain 3(4):367–377, 1997Google Scholar
  19. 19.
    Taiwo YO, Levine JD: Direct cutaneous hyperalgesia induced by adenosine. Neuroscience 38(3):756–762, 1990Google Scholar
  20. 20.
    Pappagallo M, Gaspardone A, Tomai F, Iamele M, Crea F, Gioffre PA: Analgesic effect of bamiphylline on pain induced by intradermal injection of adenosine. Pain 53(2):199–204, 1993Google Scholar
  21. 21.
    Sawynok J, Yaksh TL: Caffeine as an analgesic adjuvant: a review of pharmacology and mechanism of action. Pharmacol Rev 45(1):43–85, 1993Google Scholar
  22. 22.
    Minton NA, Henry JA: Pharmacodynamic interaction between infused adenosine and oral theophylline. Hum Exp Toxicol 10(6):411–418, 1991Google Scholar
  23. 23.
    Rao SSC, Hayek B, Summers RW: Impedance planimetry: an integrated approach for assessing sensory, active and passive biomechanical properties of the esophagus. Am J Gastroenterol 90(3):431–438, 1995Google Scholar
  24. 24.
    Patel RS, Rao SSC: Biomechanical and sensory parameters of the esophagus at four levels. Am J Physiol 275(2 Pt 1):G187–G191, 1998Google Scholar
  25. 25.
    Gregersen H, Djurhuus JC: Impedance planimetry: A new approach to biomechanical intestinal wall properties. Dig Dis Sci 9(6):332–340, 1991Google Scholar
  26. 26.
    Mujica V, Mudipalli VR, Rao SSC: Pathophysiology of chest pain in patients with nutcracker esophagus. Am J Gastroenterol 2001 (in press)Google Scholar
  27. 27.
    Orvar K, Gregersen H, Christensen J: Biomechanical characteristics of the human esophagus. Dig Dis Sci 38(2):197–205, 1993Google Scholar
  28. 28.
    Offma, JJ, Gralnek IM, Udani J, Fennerty MB, Fass R: The cost-effectiveness of omeprazole tests in patients with noncardiac chest pain. Am J Med 17(3):219–227, 1999Google Scholar
  29. 29.
    Achem SR, DeVault KR: Unexplained chest pain at the turn of the century. Am J Gastroenterol 94(1):5–8, 1999Google Scholar
  30. 30.
    Fass R, Fennerty MB, Johnson C, Camargo L, Sampliner RE: Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patients with noncardiac chest pain due to gastroesophageal reflux disease. J Clin Gastroenterol 28(1):36–39, 1999Google Scholar
  31. 31.
    Cannon RO 3rd, Quyyumi AA, Mincemoyer R, Stine AM, Gracely RH, Smith WB, et al: Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 330(20):1411–1417, 1994Google Scholar
  32. 32.
    Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS: Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology. 92(4):1027–1036, 1987Google Scholar
  33. 33.
    Rao SSC, Hayek, Summers RW: Unexplained chest pain: Esophageal hypersensitivity or motor dysfunction? Am J Gastroenterol 96(8):2584–2589, 2001Google Scholar
  34. 34.
    Richter JE, Dalton CB, Buice RG, Castell DO: Nifedepine: a potent inhibitor of contractions in the body of human esophagus: studies in healthy volunteers and patients with Nutcracker esophagus. Dig Dis Sci 89(3):549–554, 1985Google Scholar
  35. 35.
    Bertrand C, Nadel JA, Yamawaki I, Geppetti P: Role of kinins in the vascular extravasation evoked by antigen and mediated by tachykinins in guinea pig trachea. J Immunol 151(9):4902–4907, 1993Google Scholar
  36. 36.
    Julia V, Su X, Bueno L, Gebhart GF: Role of neurokinin 3 receptors on responses to colorectal distention in the rat: electrophysiological and behavioral studies. Gastroenterology 116(5):1124–1131, 1999Google Scholar
  37. 37.
    Krysiak PS, Preiksaitis HG: Tachykinins contribute to nerve mediated contractions in human esophagus. Gastroenterology 120:39–48, 2001Google Scholar
  38. 38.
    Ploudre V, St-Pierre S, Quirion R: Calcitonin gene-related peptide in viscerosensitive response to colorectal distension in rats. Am J Physiol 273(1 Pt 1):G191–G196, 1997Google Scholar
  39. 39.
    Edlund A, Conradsson T, Sollevi A: A role for adenosine in coronary vasoregulation in man. Effects of theophylline and enprofylline. Clin Physiol 15(6):623–636, 1995Google Scholar
  40. 40.
    Lanza GA, Gaspardone A, Pasceri V, Perino M, Colonna G, Tomai F, et al: Effects of bamiphylline on exercise testing in patients with syndrome X. G Ital Cardiol 27(1):50–54, 1997Google Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  • Satish S.C. Rao
    • 1
  • Ranjit S. Mudipalli
    • 1
  • Victor Mujica
    • 1
  • Craig L. Utech
    • 1
  • Xing Zhao
    • 1
  • Jeffrey L. Conklin
    • 2
  1. 1.Department of Internal MedicineUniversity of Iowa College of MedicineIowa CityUSA
  2. 2.Department of GastroenterologyMayo ClinicRochesterUSA

Personalised recommendations